Greenville, MS5 Active Studies

Ankylosing Spondylitis Clinical Trials in Greenville, MS

Find 5 actively recruiting ankylosing spondylitis clinical trials in Greenville, MS. Connect with local research sites and explore new treatment options.

5
Active Trials
5
Sponsors
2,538
Enrolling

Recruiting Ankylosing Spondylitis Studies in Greenville

About Ankylosing Spondylitis Clinical Trials in Greenville

Ankylosing spondylitis is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, causing pain, stiffness, and potentially spinal fusion. It typically begins in early adulthood. Treatment includes NSAIDs, biologics (TNF and IL-17 inhibitors), and physical therapy.

There are currently 5 ankylosing spondylitis clinical trials recruiting participants in Greenville, MS. These studies are seeking a combined 2,538 participants. Research is being sponsored by Corcym S.r.l, AstraZeneca, Kyowa Kirin Co., Ltd. and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Ankylosing Spondylitis Clinical Trials in Greenville — FAQ

Are there ankylosing spondylitis clinical trials in Greenville?

Yes, there are 5 ankylosing spondylitis clinical trials currently recruiting in Greenville, MS. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Greenville?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Greenville research site will contact you about next steps.

Are clinical trials in Greenville free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Greenville studies also compensate for your time and travel.

What ankylosing spondylitis treatments are being tested?

The 5 active trials in Greenville are testing new therapies including novel drugs, biologics, and treatment approaches for ankylosing spondylitis.

Data updated July 13, 2026 from ClinicalTrials.gov